2021•PubMedOpen access

Scleromyxedema Without Monoclonal Gammopathy Treated with Intravenous Immunoglobulins.

Mathilde Letzelter, Xavier Grimaux

Open full text 1 citations

Abstract

Scleromyxedema is a generalized cutaneous mucinosis that may cause internal damage. This condition is frequently associated with monoclonal gammopathy. However, its physiopathological implications remains uncertain. The natural development of scleromyxedema is unpredictable and may lead to potentially fatal complications. Although there is no standardized treatment, intravenous immunoglobulins are considered the best method for treating scleromyxedema. The effects of this method of treatment on this condition are not well known, and it could be argued that intravenous immunoglobulins interact with the monoclonal gammopathy. This paper describes a case of scleromyxedema without associated monoclonal gammopathy that was treated effectively using monthly courses of treatment with intravenous immunoglobulins.

About this research paper

What this paper is about

Scleromyxedema is a generalized cutaneous mucinosis that may cause internal damage. This condition is frequently associated with monoclonal gammopathy. However, its physiopathological implications remains uncertain. The natural development of scleromyxedema is unpredictable and may lead to potentially fatal complications. Although there is no standardized treatment, intravenous immunoglobulins are considered the best method for treating scleromyxedema. The effects of this method of treatment on this condition are not well known, and it could be argued that intravenous immunoglobulins interact with the monoclonal gammopathy. This paper describes a case of scleromyxedema without associated monoclonal gammopathy that was treated effectively using monthly courses of treatment with intravenous immunoglobulins.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Scleromyxedema is a generalized cutaneous mucinosis that may cause internal damage. This condition is frequently associated with monoclonal gammopathy. However, its physiopathological implications remains uncertain. The natural development of scleromyxedema is unpredictable and may lead to potentially fatal complications. Although there is no standardized treatment, intravenous immunoglobulins are considered the best method for treating scleromyxedema. The effects of this method of treatment on this condition are not well known, and it could be argued that intravenous immunoglobulins interact with the monoclonal gammopathy. This paper describes a case of scleromyxedema without associated monoclonal gammopathy that was treated effectively using monthly courses of treatment with intravenous immunoglobulins.

Key concepts: Monoclonal gammopathy, Medicine, Gammopathy, Paraproteinemias, Intravenous Immunoglobulins, Antibody, Dermatology, Monoclonal antibody

Related papers

Back to paper searchBrowse research topicsOriginal source
Scleromyxedema Without Monoclonal Gammopathy Treated with Intravenous Immunoglobulins. — Research Paper | ScholarLens